BioCryst (BCRX) Revenue by Segment

Separates income by business lines—such as product sales, royalties, licensing, and collaboration or milestone payments—to reveal whether BioCryst depends on one commercial product or partner. A diversified segment mix suggests multiple revenue engines and steadier cash flow, whereas reliance on a single segment increases sensitivity to clinical, commercial, or partner-related setbacks.

Orladeyo is the clear recurring-growth engine—strong U.S. commercialization and high S&M ROI underpin multi‑year momentum and management’s ~13% ex‑Europe 2026 revenue target, though expect a seasonal Q1 reauthorization dip. The massive 'Other' quarter is a one‑time European divestiture/proceeds item that inflates totals and shouldn’t be treated as core revenue. Watch rising 2026 R&D for navenibart and uncertain pediatric uptake as the principal near‑term risks to margin and sustained sales acceleration.